Shares of Kaleido Biosciences Inc (NASDAQ:KLDO) have been assigned a consensus broker rating score of 1.83 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company.
Analysts have set a one year consensus target price of $17.00 for the company and are forecasting that the company will post ($0.77) EPS for the current quarter, according to Zacks. Zacks has also assigned Kaleido Biosciences an industry rank of 60 out of 255 based on the ratings given to its competitors.
Several analysts have recently weighed in on KLDO shares. Goldman Sachs Group started coverage on shares of Kaleido Biosciences in a report on Monday, March 25th. They issued a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of Kaleido Biosciences in a report on Monday, March 25th. They issued a “neutral” rating and a $15.00 target price on the stock. Canaccord Genuity started coverage on shares of Kaleido Biosciences in a report on Monday, March 25th. They issued a “buy” rating and a $19.00 target price on the stock. Finally, Morgan Stanley started coverage on shares of Kaleido Biosciences in a report on Monday, March 25th. They issued an “overweight” rating and a $17.00 target price on the stock.
Shares of NASDAQ:KLDO traded up $0.81 during midday trading on Thursday, hitting $14.36. The stock had a trading volume of 2,030 shares, compared to its average volume of 85,968. Kaleido Biosciences has a 1 year low of $12.50 and a 1 year high of $15.52.
About Kaleido Biosciences
Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.